<DOC>
	<DOCNO>NCT01992536</DOCNO>
	<brief_summary>The purpose extension study evaluate immunogenicity safety booster dose MenABCWY vaccine , administer 24 month completion primary vaccination series , subject previously receive vaccine formulation study V102_03 ( NCT01272180 ) ( Groups I II ) . Antibody persistence 24 36 month primary vaccination 12 month booster dose also evaluate subject . In addition , safety immunogenicity two investigational MenABCWY vaccine formulation ( either MenABCWY+ OMV MenABCWY+¼ OMV ) assess subject previously receive two dos MenB vaccine ( Group III ) one dose Menveo vaccine ( Group IV ) . These subject follow safety immunogenicity 12 month vaccination study V102_03E1 .</brief_summary>
	<brief_title>Phase 2 , Observer-Blind , Placebo-Controlled , Randomized , Multi-Center Extension Study Evaluate Safety Immunogenicity Booster Dose MenABCWY Vaccine Administered 24 Months Following Primary Series Adolescents Young Adults Who Participated V102_03 ( NCT01272180 )</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Males females receive vaccination complete Study Termination visit primary study , V102_03 ( NCT01272180 ) ; 2 . Individuals individual 's parent legal guardian give write consent nature study explain accord local regulatory requirement ; 3 . Individuals give write assent require local regulation nature study explain accord local regulatory requirement ; 4 . Individuals good health determine outcome medical history , physical examination clinical judgment investigator ; 5 . Individuals and/or individual 's parent legal guardian comply study procedure available followup . 1 . History meningococcal vaccine administration vaccination administer primary study , V102_03 ( NCT01272180 ) ; 2 . Current previous , confirm suspected disease cause N. meningitidis ; 3 . Household contact and/or intimate exposure individual laboratory confirm N. meningitidis infection within 60 day enrollment ; 4 . History severe allergic reaction previous vaccination hypersensitivity vaccine component ; 5 . All sexually active female use `` acceptable contraceptive method ( ) '' least 2 month prior study entry . Acceptable birth control method define one following : 1 . Hormonal contraceptive ( oral , injection , transdermal patch , implant , cervical ring ) 2 . Barrier ( condom spermicide diaphragm spermicide ) every time intercourse 3 . Intrauterine device ( IUD ) 4 . Monogamous relationship vasectomize partner . Partner must vasectomize least six month prior subject 's study entry ; 6 . Sexually active female refuse use `` acceptable contraceptive method '' 3 week follow study vaccination ; 7 . Female subject positive pregnancy test prior study vaccine administer ; 8 . Nursing ( breastfeed ) mother ; 9 . Individuals history illness ongoing illness , opinion investigator , may pose additional risk subject he/she participate study ; 10 . Any serious , chronic , progressive disease ( e.g. , neoplasm , diabetes , cardiac disease , hepatic disease , progressive neurological disease seizure disorder ; autoimmune disease , HIV infection AIDS , blood dyscrasia , bleed diathesis , sign cardiac renal failure , severe malnutrition ) ; 11 . Subjects require chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior study vaccination . ( For corticosteroid , mean prednisone , equivalent , ≥ 20mg/day . Inhaled topical steroid allow ) . 12 . Receipt blood , blood product and/or plasma derivative , parenteral immunoglobulin preparation within previous 90 day ; 13 . Individuals participate clinical trial another investigational product 30 day prior first study visit intent participate another clinical study time conduct study ; 14 . Administration plan administration , vaccine foreseen study protocol within 30 day prior study vaccination , 30 day vaccination ( exception license influenza vaccine may administer &gt; 14 day precede &gt; 14 day follow study vaccination ) ; 15 . Individuals study personnel immediate family member study personnel include brother , sister , child , parent , spouse . 16 . Individuals experience moderate severe acute infection and/or fever ( defined temperature ≥ 38°C ) within 3 day prior enrolment . 17. Who receive systemic antibiotic treatment within 7 day prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Meningococcal</keyword>
	<keyword>Booster</keyword>
	<keyword>MenABCWY</keyword>
	<keyword>Menveo</keyword>
	<keyword>Vaccine Adolescents</keyword>
	<keyword>Immune Response</keyword>
	<keyword>N. Meningitidis</keyword>
</DOC>